Tag Archives: Michael Higgins

Ladenburg Thalmann & Co. Thinks Marinus’ Stock is Going to Recover

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Marinus (MRNS – Research Report), with a price target of $3. The company’s shares closed yesterday at $1.16, close to its 52-week low

Ladenburg Thalmann & Co. Reiterates a Buy Rating on Arch Therapeutics Inc (ARTH)

Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Arch Therapeutics Inc (ARTH – Research Report) on August 2 and set a price target of $1.25. The company’s shares closed on Friday at $0.28, close to its

Ladenburg Thalmann & Co. Thinks Rhythm Pharmaceuticals Inc’s Stock is Going to Recover

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Rhythm Pharmaceuticals Inc (RYTM – Research Report), with a price target of $43. The company’s shares closed yesterday at $19.89, close to its

Ladenburg Thalmann & Co. Remains a Buy on Marinus (MRNS)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Marinus (MRNS – Research Report), with a price target of $3. The company’s shares closed yesterday at $0.97, close to its 52-week low

Ladenburg Thalmann & Co. Thinks Armata Pharmaceuticals Inc’s Stock is Going to Recover

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Armata Pharmaceuticals Inc (ARMP – Research Report), with a price target of $9. The company’s shares opened today at $3.40, close to its

Ladenburg Thalmann & Co. Sticks to Its Buy Rating for Cerecor Inc (CERC)

Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Cerecor Inc (CERC – Research Report) today and set a price target of $8. The company’s shares closed yesterday at $5.65. Higgins commented: “We reiterate our Buy rating